Five Prime Therapeutics Inc


+0.98 (+7.10%)

quotes and stock data delayed 15 minutes

52 wk hi

52 wk low





Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:


Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative protein therapeutics to improve the lives of patients with serious diseases. Five Prime’s product candidates have innovative mechanisms of action and address patient populations in need of better therapies. The company focuses on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime’s product candidates.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Bemarituzumab (FPA144)

Gastric/ Gastroesophageal Junction (GEJ) tumors

Phase 3



2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b

FPT155 (CD80-FC)

Advanced solid tumors

Phase 1a


Data readout

Data readout

FPA150 (B7-H4)

Breast / Ovarian / Endometrial Cancers

Phase 1b Data


Data readout

Data readout

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon